Gerald Maguire, a clinical psychiatrist and lifelong stutterer, has dedicated over two decades to studying the neurological basis of stuttering, a speech disorder affecting roughly 80 million people worldwide. Characterized by repetitions, prolongations, and silent blocks in speech, the condition has long been misunderstood, often dismissed as a behavioral issue tied to nervousness or a temporary developmental phase.
Earlier this year, Dr. Maguire established the Stuttering Treatment and Research Society, a nonprofit organization aimed at advancing neuroscientific research and improving therapeutic approaches for people who stutter. He also convened an international panel of more than 30 experts—including psychiatrists, neuroscientists, speech-language pathologists, and individuals who stutter—to develop the first consensus medical guidelines on stuttering. Published in August in Psychiatric Times, these guidelines propose classifying stuttering as a brain-based disorder closely linked with psychiatric conditions such as attention deficit hyperactivity disorder (ADHD) and Tourette’s syndrome.
The panel’s findings emphasized the limitations of current treatment methods, with 90 percent of participants rating existing therapies as only “fair” or “poor.” Traditional intervention primarily involves speech therapy focused on reducing disfluency, or interruptions in the flow of speech. However, leading professionals now advocate a broader treatment model that moves beyond reducing stuttering moments to supporting effective communication and boosting confidence.
Diane Paul, director of clinical issues in speech-language pathology at the American Speech-Language-Hearing Association (ASHA), notes that contemporary speech therapy increasingly encourages working with stuttering rather than solely attempting to eliminate it. ASHA supports an interdisciplinary approach that includes psychiatrists, but maintains that speech-language pathologists remain central to treatment.
Dr. Maguire’s research has explored psychiatric medications as potential treatments, testing drugs commonly used for ADHD, post-traumatic stress disorder, and hypertension, some of which modulate dopamine levels in the brain. Studies have observed elevated dopamine in some individuals who stutter, suggesting that medications reducing dopamine, such as the antipsychotic aripiprazole, may offer benefits, while stimulants that increase dopamine could exacerbate symptoms.
Experts caution, however, that the evidence supporting pharmaceutical treatments is limited and primarily originates from small-scale studies led by Dr. Maguire. Eric Jackson, a researcher at New York University who also stutters, acknowledges the scientific advances but expresses skepticism about the practical impact on therapy, noting that the complexity of stuttering defies simple solutions.
No medications have been approved by the Food and Drug Administration specifically for stuttering, and the relatively small population affected—about 1 percent globally—makes it a less attractive target for pharmaceutical companies, according to Gregory Snyder, a researcher at the University of Mississippi and a person who stutters.
Complicating treatment development is the heterogeneous nature of stuttering, which encompasses multiple genetic subtypes with distinct underlying mechanisms. Dr. Snyder highlights that a one-size-fits-all approach is unlikely to succeed and suggests that future therapies might be tailored to individual genetic profiles. Recent research has identified dozens of genes linked to stuttering, some expressed in the brain and others, intriguingly, in the gut microbiome, indicating a possible role of neurotransmitters produced outside the brain, such as serotonin.
Innovative approaches are also being explored, including the use of psychedelic substances like psilocybin to alter cognitive responses to stuttering and reduce associated anxiety. While these methods remain experimental, they reflect a growing recognition that stuttering involves complex neurological and psychological components.
Researchers involved in the new guidelines hope that a clearer understanding of the brain-based nature of stuttering will reduce stigma and foster more effective, multidisciplinary treatments. As Dr. Maguire states, demystifying the neurological roots of stuttering can empower individuals by shifting blame away from personal shortcomings and toward a deeper appreciation of the condition’s biological underpinnings.